STAAR Surgical (STAA) Set to Post Earnings on Wednesday

STAAR Surgical (NASDAQ:STAA) is projected to announce its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect STAAR Surgical to announce earnings of $0.0503 per share and revenue of $78.73 million for the quarter. Parties can check the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 5:30 PM ET.

STAAR Surgical (NASDAQ:STAA) last released its earnings results on Wednesday, August 12th. The medical instruments supplier reported $0.39 earnings per share for the quarter, beating analysts’ consensus estimates of $0.22 by $0.17. The business had revenue of $93.53 million during the quarter, compared to the consensus estimate of $90.60 million. The firm’s revenue for the quarter was up 111.1% on a year-over-year basis. During the same period last year, the business posted ($0.34) EPS. On average, analysts expect STAAR Surgical to post $0.39 EPS for the current fiscal year and $0.58 EPS for the next fiscal year.

STAAR Surgical Stock Up 4.0%

STAAR Surgical stock opened at $24.16 on Wednesday. STAAR Surgical has a 1-year low of $15.59 and a 1-year high of $35.87. The company has a fifty day simple moving average of $22.38 and a 200 day simple moving average of $23.51.

STAAR Surgical announced that its Board of Directors has approved a stock repurchase program on Thursday, September 24th that allows the company to buy back $50 million in shares. This buyback authorization allows the medical instruments supplier to purchase up to 5.2% of its stock through open market purchases. Share buyback programs are usually an indication that the company’s management believes its shares are undervalued.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on STAA shares. Wall Street Zen downgraded shares of STAAR Surgical from a “buy” rating to a “hold” rating in a research note on Sunday, October 18th. Zacks Research upgraded STAAR Surgical from a “hold” rating to a “strong-buy” rating in a report on Monday, October 19th. UBS Group set a $28.00 target price on STAAR Surgical in a research report on Monday, August 17th. Stifel Nicolaus upgraded STAAR Surgical from a “hold” rating to a “buy” rating and upped their target price for the stock from $28.00 to $31.00 in a report on Tuesday, September 29th. Finally, Weiss Ratings raised STAAR Surgical from a “sell (d-)” rating to a “sell (d+)” rating in a research report on Thursday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, five have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, STAAR Surgical currently has a consensus rating of “Hold” and an average price target of $28.45.

About STAAR Surgical

STAAR Surgical is a medical device company focused on ophthalmic surgery and vision correction. The company develops, manufactures and markets implantable lenses and related products designed to reduce or eliminate dependence on glasses or contact lenses.

Its principal product line is the EVO Visian Implantable Collamer Lens (ICL), a lens implanted inside the eye to correct myopia, with or without astigmatism. Unlike procedures that remove corneal tissue, ICL surgery preserves the eye’s natural lens and is designed to be removable.